17 results about "Oxepane" patented technology

This invention relates to a process for preparing compounds having formula (I): R 1 ‑C(=O)‑O‑CH2‑O‑C(=O)‑R 2 (I), where R 1 and R 2 Each of the terms represents an alkyl, cycloalkyl, or aryl group independently, wherein the alkyl, cycloalkyl, or aryl group is optionally substituted; the process includes step i) reacting the following substances: compound A selected from: trioxane, polyoxymethylene without a hydroxyl terminal group; compound (II): R 1 -C(=O)-O-C(=O)-R 2 (II); and perfluorosulfonic acid; wherein step i) is carried out at a temperature T1 of at least 50°C, wherein the molar ratio of compound (II) to compound A is 1:1 to 1.2:1.

The present invention relates: to a tablet formulation comprising crystalline Hydrate 1 Modification A form of the compound 3-(3-chloro-2-methoxy-anilino)-2-[3-[[(2S)-l,4-dioxan-2-yl]methoxy]-4-pyridyl]-1, 5,6,7- tetrahydropyrrolo[3,2-c]pyridine-4-one, of formula (A): wherein the content of water is greater than 0% (w / w), particularly greater than 0% and less than or equal to 4%, of the total weight of said compound of formula (A); to methods of preparing said tablet formulation, and to uses of said tablet formulation in the prophylaxis and / or treatment of diseases.

A process for preparing trioxane from methanol includes: step 1: subjecting a mixture of methanol and methylal to a reaction to obtain formaldehyde, and absorbing the formaldehyde with water to obtain a concentrated formaldehyde aqueous solution; step 2: subjecting the concentrated formaldehyde aqueous solution to cyclization to obtain a mixture containing trioxane, and passing the mixture through a trioxane concentration tower to obtain a crude trioxane product; step 3: converting a by-product and unreacted formaldehyde in the crude trioxane product into methanol, conducting dehydration through a membrane dehydration process, and subjecting a retentate to dealcoholization to obtain purified trioxane; and step 4: subjecting the remaining streams to reactive distillation to obtain a mixture of methanol and methylal at a top- and water at a bottom of the reactive distillation tower; returning the mixture of methanol and methylal to step 1; and returning or discharging the water.

The present application relates to carbon dioxide absorbent technical field, especially relates to a kind of ionic liquid-like carbon dioxide absorbent preparation method.The present application includes the following steps: (one) synthesis preparation: the choline chloride and urea are made into low eutectic solvent DES, polyamide amine PAMAM G1 and low eutectic solvent DES are made into absorbent;(two) mixing and heating: after drying raw material is added to heating container, add dioxane as solvent, place in oil bath, stirring heating, mixture gradually from turbid solid becomes homogeneous, transparent, viscous liquid;(three) purification and water removal: after forming homogeneous liquid, in vacuum stirring, to remove moisture, and the final product is liquid ionic liquid carbon dioxide absorbent.The beneficial effect is: the preparation method of the present application is simple and controllable, reaction condition is mild, easy to scale production, provides a feasible technical scheme for industrial application;Solve the existing absorbent active site few, the problem of low carbon dioxide capture amount.

The invention relates to a crystal form A of(S)-2-(3S,8S)-3-(4-(3,4-dichlorobenzyloxy)phenyl-7-((S)-1-phenylpropyl)-2,3,6,7,8,9-hexahydro-[1,4]-dioxino[2,3-g]isoquinolin-8-ylformylamino)-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)propionic acid (“OAD2”), and methods of preparation thereof. Crystal form A may be useful in the treatment of various conditions and metabolic disorders including, but not limited to, type 2 diabetes.

The present invention relates: to the crystalline Hydrate 1 Modification A form of the compound 3-(3-chloro-2-methoxy- anilino)-2-[3-[[(2S)-1,4-dioxan-2-yl]methoxy]-4-pyridyl]-1,5,6,7-tetrahydropyrrolo[3,2- c]pyridine-4-one of formula (A): 5 *x H 2 O (A), wherein the content of water is greater than 0 % (w / w) and ≤ 4.0 % (w / w); • to a method of preparing said crystalline Hydrate 1 Modification A form of said compound of formula (A) and to intermediate compounds used in said method;• to pharmaceutical compositions and combinations comprising said crystalline Hydrate 1 Modification A form of said compound of formula (A); and • to said crystalline Hydrate 1 Modification A form of the compound of formula (A), and to pharmaceutical compositions or combinations comprising same for use in the treatment or prevention of a cancer, such as lung cancer, particularly non-small cell lung carcinoma.

Provided are a pharmaceutically acceptable salt and a crystalline form of a GLP-1 receptor agonist and a preparation method therefor. Specifically, provided are a pharmaceutically acceptable salt and a crystalline form of a compound 2-((4-((S)-3-(4-chloro-2-fluorophenyl)-2,3-dihydrobenzo[b][1,4] dioxane-5-yl)piperidin-1-yl)methyl)-1-(((S)-oxe-tane-2-yl)methyl)-1H-benzo[d]imidazole-6-formic acid.

The present invention relates to a process of preparation of a compound having formula (I):wherein R1 and R2 represent, independently of each other, an alkyl, a cycloalkyl or an aryl group, said alkyl, cycloalkyl or aryl group being optionally substituted;said process comprising a step i) of reacting:a compound A selected from the group consisting of: trioxane, polyoxymethylene deprived of hydroxyl end groups;a compound of formula (II):anda perfluorosulfonic acid;wherein step i) is carried out at a temperature T1 of at least 50° C., wherein the molar ratio of compound of formula (II): compound A ranges from 1:1 to 1.2:1.

The present disclosure relates to a method for preparing a benzodioxane or salts thereof. Specifically, the method of the present disclosure comprises a step of reacting a compound of formula E under the presence of a tri-substituted phosphine / azodicarboxylate to form a compound of formula F.

The invention relates to the technical field of lithium metal battery electrolytes, in particular to an electrolyte, application thereof and a cathode-free lithium metal battery. The invention provides an electrolyte. The electrolyte comprises a lithium salt, a solvent, a diluent and an additive, the diluent comprises a 1, 3-dioxane derivative, acetal carbon located at the position 2 in the 1, 3-dioxane of the 1, 3-dioxane derivative is substituted by Rf1 and Rf2, and the Rf1 and the Rf2 are the same or different; the Rf1 and the Rf2 are independently fluorine substituted alkyl groups; the additive is prepared from one or more of 1, 3, 5-trioxane, a derivative of the 1, 3, 5-trioxane and paraldehyde, and the additive is prepared from one or more of 1, 3, 5-trioxane, a derivative of the 1, 3, 5-trioxane and paraldehyde. The electrolyte can give consideration to both excellent ion transmission and lithium deposition dynamic performance under a low-temperature condition.

The present invention relates to the use of 1,3-dioxolan-4-ones and 1,3-dioxan-4-ones of the formula (I)wherein R1 to R4 are as defined in the claims and the description, as aroma ingredients. Said compounds are used to impart an aroma impression, in particular a fragrance to a composition and also for enhancing and / or modifying the aroma, especially fragrance, of a composition. The present invention is further directed to a method of imparting an aroma to a composition by incorporating said compounds into the composition, to a composition comprising at least one of said compounds, and to specific 1,3-dioxolan-4-ones and 1,3-dioxan-4-ones.

The invention belongs to the technical field of organic synthesis, and particularly discloses a method for synthesizing neroli through 4-methyl-4-[(3-methylbutyl-3-alkene-1-yl) oxy]-2-(2-methylpropyl-1-alkene-1-yl) oxacyclohexane. The method comprises the following steps: taking 4-methyl-4-[(3-methylbutyl-3-alkene-1-yl) oxy]-2-(2-methylpropyl-1-alkene-1-yl) oxacyclohexane as a raw material; comprising the following steps: uniformly mixing 4-methyl-4-[(3-methylbutyl-3-alkene-1-yl) oxy]-2-(2-methylpropyl-1-alkene-1-yl) oxacyclohexane with a solvent, preheating, pumping the mixture into a fixed bed reactor filled with a SO42-Fe2O3-La2O3 / SBA-15 solid acid catalyst at a certain flow rate, reacting for a period of time at a certain temperature and pressure, filtering, washing, and drying to obtain the 4-methyl-4-[(3-methylbutyl-3-alkene-1-yl) oxy]-2-(2-methylpropyl-1-alkene-1-yl) oxacyclohexane. After the reaction, cooling through a condenser to obtain a reaction crude product, and rectifying the crude product to obtain a neroli ether product and an isopentenol byproduct; the synthesis method disclosed by the invention is relatively mild in reaction condition, high in reaction speed and high in production efficiency, no wastewater is generated in reaction post-treatment, the solvent and the catalyst can be recycled for the next batch after being recycled, the production cost is greatly reduced, and industrial production is easy to realize. Meanwhile, by-products are utilized, and the production cost of nerolin is reduced.

1 / 1 SUMMARY “METHOD FOR PROPHYLAXIS AND / OR TREATMENT OF BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE, PROPHYATIC AND / OR THERAPEUTIC AGENT FOR BEHAVIORAL SYMPTOMS AND PSYCHOLOGICAL ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE, USE OF A COMPOUND, COMPOUND, AND, PHARMACEUTICAL COMPOSITION†The present invention relates to a prophylactic and / or therapeutic for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental illness, which contains 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl) butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient.

The present application relates to carbon dioxide absorbent technical field, especially relates to a kind of ionic liquid-like carbon dioxide absorbent preparation method.The present application includes the following steps: (one) synthesis preparation: the choline chloride and urea are made into low eutectic solvent DES, polyamide amine PAMAM G1 and low eutectic solvent DES are made into absorbent;(two) mixing and heating: after drying raw material is added to heating container, add dioxane as solvent, place in oil bath, stirring heating, mixture gradually from turbid solid becomes homogeneous, transparent, viscous liquid;(three) purification and water removal: after forming homogeneous liquid, in vacuum stirring, to remove moisture, and the final product is liquid ionic liquid carbon dioxide absorbent.The beneficial effect is: the preparation method of the present application is simple and controllable, reaction condition is mild, easy to scale production, provides a feasible technical scheme for industrial application;Solve the existing absorbent active site few, the problem of low carbon dioxide capture amount.

This invention discloses a method for preparing high-purity fodosteine, belonging to the field of pharmaceutical chemical synthesis technology. The method uses L-cysteine ​​and 1,3-dioxane-2-one as starting materials, without adding solvent. The reaction is induced by heating under a catalytic amount of alkali. The crude product is precipitated by adding ethanol, and purified fodosteine ​​is obtained by recrystallization. The product yield is as high as 96.6%, and the HPLC purity is as high as 99.94%. The preparation method of this invention only adds a catalytic amount of alkali, does not affect the product's ignition residue, does not require multiple recrystallizations or ion exchange resin desalting, and has an unknown impurity content as low as 0.02%. The entire process is safe, simple, and environmentally friendly, making it suitable for industrial production.

The invention discloses a hyperbranched polymer-based composite film adhesive as well as a preparation method and application thereof. The hyperbranched polymer disclosed by the invention is obtained by carrying out copolymerization reaction on methacrylic acid, poly (ethylene glycol) methacrylate, carbamidinone methacrylate, 2-methylene-1, 3-dioxane and 2-(2-methoxyethoxy) ethyl methacrylate, and the hyperbranched polymer disclosed by the invention is obtained by carrying out copolymerization reaction on methacrylic acid, poly (ethylene glycol) methacrylate, carbamidinone methacrylate, 2-methylene-1, 3-dioxane and 2-(2-methoxyethoxy) ethyl methacrylate. The hyperbranched polymer and a certain proportion of nanocellulose are dissolved and dried to form a composite film. The composite film has good mechanical properties, thermosensitivity, degradability and biocompatibility, and shows good adhesion strength to skin tissues. The hyperbranched polymer disclosed by the invention is simple, convenient and safe to synthesize, and the composite film disclosed by the invention is convenient to use and has relatively high application and popularization values.